(Q34697474)

4 August 2017

1 reference

title

Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide (English)

1 reference

4 August 2017

1 reference

Florian Kreppel

1

1 reference

4 August 2017

Stefan Kochanek

series ordinal

2

1 reference

4 August 2017

publication date

2 October 2007

1 reference

4 August 2017

1 reference

4 August 2017

volume

16

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

16-29

1 reference

Adenoviral vectors for gene transfer and therapy

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Adenoviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Characterization of an adenovirus gene transfer vector containing an E4 deletion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

High-capacity adenoviral vectors for gene transfer and somatic gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for ch

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

The innate immune response to adenovirus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Transductional targeting of adenovirus vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

The influence of adenovirus fiber structure and function on vector development for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Current advances and future challenges in Adenoviral vector biology and targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

The influence of blood on in vivo adenovirus bio-distribution and transduction.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Novel delivery technologies for protein and peptide therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Polymer therapeutics: concepts and applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEGylation, successful approach to drug delivery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEG-adenosine deaminase and PEG-asparaginase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Increased transduction of skeletal muscle cells by fibroblast growth factor-modified adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Stepwise dismantling of adenovirus 2 during entry into cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Toward synthetic viruses: endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

pH-responsive shielding of non-viral gene vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Blood clearance rates of adenovirus type 5 in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Clinical Implications of N-(2-Hydroxypropyl)Methacrylamide Copolymers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Investigations of PEGylated recombinant adenovirus, using fluorescein-labeled polyethylene glycol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300321

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300321

1 reference

4 August 2017

1 reference